Recurring hypersomnias are described according to 3 etiological groups: 1) idiopathic - the Kleine Levin syndrome and its clinical variants - 2) organic and 3) psychiatric. The typical form of the Kleine Levin syndrome is remarkable for the association of recurring episodes of sleep, overeating and temporary mental disturbances lasting from a few hours to several days. Its diagnosis is mainly based on clinical data Laboratory investigations have so far failed to document specific features. Emphasis is laid on circumstances at onset and pathological studies which could be in favour of a viral origin. Some clinical aspects and polysomnographic features are reminiscent of endogenous depression. The treatments of hypersomniac episodes based on stimulants are often disappointing. On the other hand, the prevention of the hypersomniac episodes of the Kleine Levin syndrome with lithium carbonate has been successful in several well-documented cases as well as the prevention of the hypersomniac episodes of the menstruation related hypersomnia with ovulatory inhibitors. Organic and psychiatric forms of recurring hypersomnias are not well known. Their clinical features are described and their various possible etiologies indicated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PROTOCOL: Mutual Help Organizations to Support Recovery Among Individuals Who Use Drugs: A Systematic Review Protocol.
Campbell Syst Rev
March 2025
Harvard Medical School, Recovery Research Institute Boston Massachusetts USA.
This is the protocol for a Campbell systematic review. The objectives are as follows: (1) What kinds of mutual-help organizations for drug use disorders have been studied with evidence available in the empirical literature? (2) What is the nature of the evidence with regard to the different types of mutual-help organizations?-(a) To what extent are these entities shown to help initiate, sustain, and enhance rates of remission from drug use disorders and improve other functional outcomes when the available evidence is subjected to rigorous scientific scrutiny? (b) To what extent do different mutual-help organizations confer differential benefit and to whom, how, and over what period? (c) To what extent have cost benefit or cost effectiveness studies indicated that these entities are cost-effective?
View Article and Find Full Text PDFActigraphy against 32-hour polysomnography in patients with suspected idiopathic hypersomnia.
J Sleep Res
February 2025
Institute of Neurosciences of Montpellier (INM), University of Montpellier, INSERM, Montpellier, France.
Actigraphy, a tool known for investigating sleep-wake patterns at home, lacks scientific validation in hypersomnolent subjects. We aim to validate an actigraphy-based sleep-wake prediction algorithm against 32-h continuous polysomnography in patients with suspected idiopathic hypersomnia, and to compare its performance to predict sleep-wake parameters assessed by polysomnography with those of a commercially available algorithm. Two hundred and six hypersomnolent subjects were included prospectively in a Reference Centre for Hypersomnias, and underwent a 32-h bedrest protocol, wearing wrist-actigraphy, to diagnose idiopathic hypersomnia.
View Article and Find Full Text PDFSafety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.
medRxiv
January 2025
Neuroscience Research Australia, Sydney, NSW, Australia.
Background: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an ongoing platform trial assessing the safety and efficacy of multiple investigational products in participants with dominantly inherited Alzheimer's disease (DIAD) caused by mutations. On the basis of findings of amyloid removal and downstream biological effects from the gantenerumab arm of the platform trial, we continued a 3-year open-label extension (OLE) study to assess the safety and efficacy of long-term treatment with high doses of gantenerumab.
View Article and Find Full Text PDFTreatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.
Eur J Haematol
February 2025
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Approximately 40%-60% of patients reaching a stable deep molecular response during TKI treatment will maintain a state of remission after TKI discontinuation, denoted as treatment-free remission (TFR). Depth of molecular response assessed by BCR::ABL1 digital PCR prior to TKI discontinuation has demonstrated its significance as a reliable predictive parameter for TFR. A clinically applicable prediction cutoff of 0.
View Article and Find Full Text PDFA search is presented for an extended Higgs sector with two new particles, X and ϕ, in the process X→ϕϕ→(γγ)(γγ). Novel neural networks classify events with diphotons that are merged and determine the diphoton masses. The search uses LHC proton-proton collision data at sqrt[s]=13 TeV collected with the CMS detector, corresponding to an integrated luminosity of 138 fb^{-1}.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!